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LETTER TO THE EDITOR 
EFFECT OF DANAZOL ON CYCLOSPORINE PHARMACOKINETICS' 
Danazol, a derivative of ethisterone is an inhibitor of pitui-
tary gonadotrophins and a weak androgen. It is increasingly 
used in endometriosis and fibrocystic mastopathy. There has 
been only a single report of its effect on cyclosporine (CsA *) 
pharmacokinetics in a kidney transplant recipient in the liter-
ature in English (1). 
One of our patients, a 47-year-old woman with primary 
biliary cirrhosis, received an orthotopic liver transplant in 
January 1986. The patient began having irregular heavy vaginal 
bleeding in April 1986. At this time, she was taking CsA 150 
mg p.o. b.i.d.; prednisone 10 mg q.d., azathioprine 25 mg q.d., 
and lasix 40 mg q.d. She was placed on intermittent norethin-
drone (Norlutate) 15 mg p.o. q.d. This did not have any effect 
on her vaginal bleeding, cyclosporine levels, or liver functions 
over a period of 3 months. The patient was eventually started 
on danazol 200 mg p.o. q.i.d. Within days of starting danazol 
her CsA levels increased, along with a rise in transaminase 
values. There was no change in bilirubin and alkaline phospha-
tase levels (Table 1). After stopping danazol, CsA, transami-
nases, and creatinine levels reached previous values_ 
The rise in CsA levels could reflect increased intestinal 
absorption or decreased breakdown in the liver. There have 
been reports of inhibition by some sex steroids of hepatic 
microsomal enzyme systems (2) that increases CsA levels_ It is 
more than likely that the rise in CsA levels seen in our patient 
is a result of a decrease in CsA breakdown by the liver rather 
than increased absorption. In a series of nontransplant patients 
danazol has been reported to cause elevation of hepatic trans-
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• Abbreviations used: CsA, cyclosporine; SGOT, serum glutamic 
oxaloacetic transaminase; RIA, radioimmunoassay; SGPT, serum glu-
tamic pyruvic transaminase. 
aminases in a small minority of cases when given in doses of 
800 mg/day (3). The other possibility, that hepatic transami-
nase elevations in our patient are secondary to CsA hepato-
toxicity, is unlikely because of the absence of changes in bili-
rubin and alkaline phosphatase (4). The progestational agent 
norethindrone did not affect the CsA levels or liver functions 
when given intermittently. Hence caution is indicated when 
starting patients taking CsA on danazol or other sex steroids. 
CsA levels should be measured and liver function tests per-
formed frequently. 
BABURAO KONERU 2 
CAROLYN HARTNER 
SHUNZABURO Iw ATSUKI 
THOMAS E. STARZL 
The Department of Surgery 
University Health Center of Pittsburgh 
University of Pittsburgh 
The Veterans Administration Medical Center 
Pittsburgh, Pennsylvania 15213 
2 Address correspondence to: Baburao Koneru. 4 West Falk Clinic, 
3601 Fifth Avenue, Pittsburgh, PA 15213. 
REFERENCES 
1. Ross WB, Roberts D, Griffin PJA, Salam an JR. Cyciosporine 
interaction with Danazol and Norethisterone. Lancet 1986; 1: 
330. 
2. Maurer G. Metabolism of cycJosporine. Transplant Proc 1985 
17(suppl 1): 19. 
3. Spooner JB. Classification of side effects to Danazol therapy. J Int 
Med Res 1977; 5(suppl 3): 15. 
4. Lorber MI, VanBuren CT, Flechner SM, Williams C, Kahan BD. 
Hepatobiliary and pancreatic complications of cyciosporine ther-
apy in 466 renal transplant recipients. Transplantation 1987; 43: 
35. 
TABLE L Cyclosporine levels, liver functions, and creatinine values before, during, and after danazol therapy 
esA level (RIA) Total SGPTjSGOT Alkaline Creatinine Date (ng/ml) bilirubin (UlL) phosphatase (mg/dl) (mg/dl) (V/L) 
3/23/87 305 0.7 4/9 68 2'} 4/13/87 319 0.8 10/15 58 2.2 
5/14/87 238 0.6 11/11 65 2.2 Norethindrone given 
intermittently 
6/1/87 224 0.6 8/5 60 2. I Danazol 200 mg q.i.d. 7/31/87 
8/11/87 812 
8/14/87 724 
8/25/87 1034 0.7 253/111 62 2.9 Danazol stopped 
8/27/87 734 0.6 249/90 52 2.6 CsA dose to 125 mg bj.d. 
8/31/87 595 0.5 122/29 55 2.3 
9/21/87 269 0.6 21/10 68 2.3 
10/5/87 287 0.5 21/17 71 2.3 
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